Yanlei Zhang

6PUBLICATIONS
26CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 21, 2026
Anti-BCMA/GPRC5D CAR T in relapsed or refractory multiple myeloma patients with extraosseous extramedullary disease.

|Feb 27, 2026
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).

Wenqiang Yan, Chenxing Du, Rui Lv

|Jul 25, 2025
Donor-derived CD7 CAR T cells for pediatric and adult relapsed/refractory T-ALL/LBL: a phase 2 trial.

Jing Pan, Liping Zhao, Yibing Zhang

|Mar 07, 2023
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.

Jieyun Xia, Hujun Li, Zhiling Yan

|Jul 29, 2021
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.

Jing Pan, Yue Tan, Guoling Wang

|Jul 22, 2021
CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study.

Guoqing Wei, Yanlei Zhang, Houli Zhao

Pageof 1

Frequent Collaborators

2 joint publications

Jing Pan

2 joint publications

Samuel Seery

2 joint publications

Yuekun Qi

2 joint publications

Feng Zhu